Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  199,101 results for "%22INFLIXIMAB%22"

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

The impact of proactive versus reactive drug monitoring of infliximab on treatment outcomes in patients with crohn's disease.

  • Authors : Zhang Y; Department of Gastroenterology, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, China.; Jiang W

Subjects: Crohn Disease*/Crohn Disease*/Crohn Disease*/drug therapy ; Drug Monitoring* ; Gastrointestinal Agents*/Gastrointestinal Agents*/Gastrointestinal Agents*/adverse effects

  • Source: Scandinavian journal of gastroenterology [Scand J Gastroenterol] 2024 Mar; Vol. 59 (3), pp. 269-279. Date of Electronic Publication: 2023 Nov 22.Publisher: Informa Healthcare Country of Publication: England NLM ID: 0060105 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Infliximab rescue therapy in a case of severe granulomatous colitis associated with rituximab use.

Subjects: Colitis*/Colitis*/Colitis*/chemically induced ; Colitis*/Colitis*/Colitis*/drug therapy ; Crohn Disease*/Crohn Disease*/Crohn Disease*/drug therapy

  • Source: BMJ case reports [BMJ Case Rep] 2024 Feb 29; Vol. 17 (2). Date of Electronic Publication: 2024 Feb 29.Publisher: BMJ Pub. Group Country of Publication: England NLM ID: 101526291 Publication Model: Electronic Cited Medium: Internet ISSN: 1757-790X

Record details

Read More Add to Saved list
×
Academic Journal

Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing.

  • Authors : Keating PE; Immunology Section, Canterbury Health Laboratories, Christchurch, New Zealand.; Hock BD

Subjects: Adalimumab*/Adalimumab*/Adalimumab*/therapeutic use ; Infliximab*/Infliximab*/Infliximab*/therapeutic use; Humans

  • Source: Internal medicine journal [Intern Med J] 2023 Nov; Vol. 53 (11), pp. 2123-2127.Publisher: Blackwell Science Asia Country of Publication: Australia NLM ID: 101092952 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Effectiveness of Adjunctive High-Dose Infliximab Therapy to Improve Disability-Free Survival Among Patients With Severe Central Nervous System Tuberculosis: A Matched Retrospective Cohort Study.

  • Authors : Manesh A; Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.; Gautam P

Subjects: Disabled Persons* ; Infliximab*/Infliximab*/Infliximab*/adverse effects ; Infliximab*/Infliximab*/Infliximab*/pharmacology

  • Source: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 Nov 17; Vol. 77 (10), pp. 1460-1467.Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

HLA-DQA1*05 and upstream variants of PPARGC1B are associated with infliximab persistence in Japanese Crohn's disease patients.

Subjects: Crohn Disease*/Crohn Disease*/Crohn Disease*/drug therapy ; Crohn Disease*/Crohn Disease*/Crohn Disease*/genetics ; Infliximab*/Infliximab*/Infliximab*/therapeutic use

  • Source: The pharmacogenomics journal [Pharmacogenomics J] 2023 Nov; Vol. 23 (6), pp. 141-148. Date of Electronic Publication: 2023 Jul 17.Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101083949 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Remarkable effects of infliximab on severe radiation-induced side effects in a patient with uterine cervical cancer: a case report.

  • Authors : Toft Morén A; Division of Clinical Cancer Epidemiology, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sweden.; Bull C

Subjects: Infliximab*/Infliximab*/Infliximab*/therapeutic use ; Radiation Injuries*/Radiation Injuries*/Radiation Injuries*/drug therapy ; Radiation Injuries*/Radiation Injuries*/Radiation Injuries*/etiology

  • Source: The Journal of international medical research [J Int Med Res] 2023 Dec; Vol. 51 (12), pp. 3000605231208596.Publisher: Sage Publications Country of Publication: England NLM ID: 0346411 Publication Model: Print Cited Medium: Internet ISSN: 1473-2300

Record details

Read More Add to Saved list
×
Academic Journal

Infliximab substantially re-silenced Wnt/β-catenin signaling and ameliorated doxorubicin-induced cardiomyopathy in rats.

  • Authors : Mohamed HE; Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.; Askar ME

Subjects: Cardiomyopathies*/Cardiomyopathies*/Cardiomyopathies*/chemically induced ; Cardiomyopathies*/Cardiomyopathies*/Cardiomyopathies*/drug therapy ; Infliximab*

  • Source: Journal of biochemical and molecular toxicology [J Biochem Mol Toxicol] 2023 May; Vol. 37 (5), pp. e23312. Date of Electronic Publication: 2023 Jan 13.Publisher: Wiley Country of Publication: United States NLM ID: 9717231 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1099-0461

Record details

Read More Add to Saved list
×
Academic Journal

Exploring treatment of inflammatory bowel disease with infliximab in the Middle East and Northern Africa: An analysis of the HARIR observational cohort study.

  • Authors : Alharbi O; Gastroenterology Section, King Khalid University Hospital, College of Medicine, King Saud University, Riyadh, Saudi Arabia.; Hamed W

Subjects: Biological Products* ; Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/drug therapy ; Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/epidemiology

  • Source: Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association [Saudi J Gastroenterol] 2023 May-Jun; Vol. 29 (3), pp. 164-170.Publisher: Medknow Publications Country of Publication: India NLM ID: 9516979 Publication Model: Print Cited Medium: Internet ISSN: 1998-4049

Record details

Read More Add to Saved list
×
Academic Journal

90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients.

  • Authors : Pesole PL; National Institute of Gastroenterology-IRCCS, 'Saverio de Bellis', 70013 Castellana Grotte, Italy.; Liso M

Subjects: Biological Products*/Biological Products*/Biological Products*/therapeutic use ; Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/drug therapy ; Crohn Disease*/Crohn Disease*/Crohn Disease*/drug therapy

  • Source: International journal of molecular sciences [Int J Mol Sci] 2023 Feb 16; Vol. 24 (4). Date of Electronic Publication: 2023 Feb 16.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

Record details

Read More Add to Saved list
×
Report

Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine.

Subjects: COVID-19 Vaccines* ; Infliximab* ; Janus Kinase Inhibitors*SARS-CoV-2 variants

  • Source: Gastroenterology [Gastroenterology] 2023 Feb; Vol. 164 (2), pp. 300-303.e3. Date of Electronic Publication: 2022 Oct 19.Publisher: W.B. Saunders Country of Publication: United States NLM ID: 0374630 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  199,101 results for "%22INFLIXIMAB%22"